SIBN Stock Analysis: Si-Bone | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 824m USD | 12M Return: 26.4% | US8257041090 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 10.4M
Qual. Beats: 6
Rev. Trend: 99.7%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 7.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
SI-Bone, Inc. (NASDAQ: SIBN) is a U.S.-based medical device company founded in 2008 and headquartered in Santa Clara, California. The company specializes in procedural solutions for compromised bone, with a focus on implants designed for the sacroiliac (SI) joint. Its core product family, the iFuse system, consists of patented triangular titanium implants and related instruments used to stabilize the joint and promote bone fusion, with multiple product variants (iFuse, iFuse 3D, iFuse Bone, iFuse Torq, iFuse Bedrock Granite, and iFuse Torq TNT) serving different surgical applications.
The company sells primarily through a direct sales force supplemented by third-party sales agents and resellers, a distribution model common among specialized orthopedic device manufacturers targeting surgeons and hospitals. SI-Bone went public in October 2018 and is classified within the Health Care sector (Health Care Supplies sub-industry) as a small-cap company.
- US iFuse procedure volume growth drives top-line expansion
- CMS reimbursement coverage supports broader surgeon adoption
- New TORQ and Bedrock Granite product launches expand addressable market
| Net Income: -14.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 5.59 > 1.0 |
| NWC/Revenue: 91.70% < 20% (prev 98.62%; Δ -6.92% < -1%) |
| CFO/TA 0.01 > 3% & CFO 2.48m > Net Income -14.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 9.15 > 1.5 & < 3 |
| Outstanding Shares: last quarter (44.2m) vs 12m ago 3.35% < -2% |
| Gross Margin: 79.53% > 18% (prev 79.45%; Δ 0.08% > 0.5%) |
| Asset Turnover: 89.06% > 50% (prev 80.23%; Δ 8.83% > 0%) |
| Interest Coverage Ratio: -5.41 > 6 (EBIT TTM -13.5m / Interest Expense TTM 2.49m) |
| A: 0.79 (Total Current Assets 219.9m - Total Current Liabilities 24.0m) / Total Assets 248.8m |
| B: -1.84 (Retained Earnings -458.7m / Total Assets 248.8m) |
| C: -0.06 (EBIT TTM -13.5m / Avg Total Assets 239.8m) |
| D: 2.75 (Book Value of Equity 182.3m / Total Liabilities 66.4m) |
| Altman-Z'' = 1.66 = BB |
| DSRI: 1.11 (Receivables 31.2m/24.4m, Revenue 213.6m/185.3m) |
| GMI: 1.00 (GM 79.45% / 79.53%) |
| AQI: 0.66 (AQ_t 0.00 / AQ_t-1 0.00) |
| SGI: 1.15 (Revenue 213.6m / 185.3m) |
| TATA: -0.07 (NI -14.6m - CFO 2.48m) / TA 248.8m) |
| Beneish M = -3.04 (Cap -4..+1) = AA |
As of October 03, 2026, the stock is trading at USD 18.08 with a total of 547,322 shares traded. Over the past week, the price has changed by -2.74%, over one month by -5.64%, over three months by +5.67% and over the past year by +26.35%.
Current recommended Stop Loss: 17.30 (which is 4.3% or 1.2 ATR below the current price).
Si-Bone has received a consensus analysts rating of 4.56. Therefore, it is recommended to buy SIBN.
- StrongBuy: 5
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 25 | 38.3% |
P/S = 3.8597
P/B = 4.6233
Revenue TTM = 213.6m USD
EBIT TTM = -13.5m USD
EBITDA TTM = -5.00m USD
Long Term Debt = 35.6m USD (from longTermDebt, last quarter)
Short Term Debt = 426k USD (from shortTermDebt, last quarter)
Debt = 43.2m USD (corrected: LT Debt 35.6m + ST Debt 426k) + Leases 7.17m
Net Debt = -102.7m USD (calculated: Debt 43.2m - CCE 145.9m)
Enterprise Value = 721.7m USD (824.5m + Debt 43.2m - CCE 145.9m)
Interest Coverage Ratio = -5.41 (Ebit TTM -13.5m / Interest Expense TTM 2.49m)
EV/FCF = 64.58x (Enterprise Value 721.7m / FCF TTM 11.2m)
FCF Yield = 1.55% (FCF TTM 11.2m / Enterprise Value 721.7m)
FCF Margin = 5.23% (FCF TTM 11.2m / Revenue TTM 213.6m)
Net Margin = -6.85% (Net Income TTM -14.6m / Revenue TTM 213.6m)
Gross Margin = 79.53% ((Revenue TTM 213.6m - Cost of Revenue TTM 43.7m) / Revenue TTM)
Gross Margin QoQ = 79.54% (prev 79.76%)
Tobins Q-Ratio = 2.90 (Enterprise Value 721.7m / Total Assets 248.8m)
Interest Expense / Debt = 5.76% (Interest Expense 2.49m / Debt 43.2m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -10.6m (EBIT -13.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.75 (Total Current Assets 219.9m / Total Current Liabilities 32.6m)
Debt / Equity = 0.24 (Debt 43.2m / totalStockholderEquity, last quarter 182.3m)
Debt / EBITDA = 20.55 (negative EBITDA) (Net Debt -102.7m / EBITDA -5.00m)
Debt / FCF = -9.19 (Net Debt -102.7m / FCF TTM 11.2m)
Total Stockholder Equity = 177.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -6.10% (Net Income -14.6m / Total Assets 248.8m)
RoE = -8.23% (Net Income TTM -14.6m / Total Stockholder Equity 177.7m)
RoCE = -6.31% (EBIT -13.5m / Capital Employed (Equity 177.7m + L.T.Debt 35.6m))
RoIC = -4.96% (negative operating profit) (NOPAT -10.6m / Invested Capital 214.5m)
WACC = 8.96% (E(824.5m)/V(867.7m) * Re(9.19%) + D(43.2m)/V(867.7m) * Rd(5.76%) * (1-Tc(0.21)))
Discount Rate = 9.19% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 99.92 | Cagr: 3.49%
[DCF] Terminal Value 73.33% ; FCFF base≈11.2m ; Y1≈11.2m ; Y5≈11.9m
[DCF] Fair Price = 6.09 (EV 167.5m - Net Debt -102.7m = Equity 270.2m / Shares 44.3m; r=8.96% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 2.51 | # QB: 6
Revenue Correlation: 99.71 | Revenue CAGR: 19.92% | SUE: 0.66 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.13 | Chg30d=+1.46% | Revisions=-38% | Analysts=8
EPS current Year (2026-12-31): EPS=-0.40 | Chg30d=+7.26% | Revisions=+44% | GrowthEPS=+9.7% | GrowthRev=+15.5%
EPS next Year (2027-12-31): EPS=-0.33 | Chg30d=+6.26% | Revisions=+29% | GrowthEPS=+16.8% | GrowthRev=+15.6%
[Analyst] Revisions Ratio: +17% (up=9, down=6)